Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MTOR | P42345 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380151 | 0.98 | TRPV1 (0.70) | TRPV1MAPTHPGDMEN1TP53 | |
| SCHEMBL9808674 | 0.98 | TRPV1 (0.70) | TRPV1MAPTHPGDMEN1TP53 | |
| SCHEMBL504257 | 0.98 | TRPV1 (0.70) | TRPV1MAPTHPGDMEN1TP53 | |
| SCHEMBL504255 | 0.98 | TRPV1 (0.70) | TRPV1MAPTHPGDMEN1TP53 | |
| SCHEMBL1585893 | 0.93 | TRPV1 (0.61) | TRPV1MAPTHPGDMEN1TP53 | |
| SCHEMBL29530847 | 0.91 | TRPV1 (0.74) | TRPV1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28755565 | 0.91 | TRPV1 (0.74) | TRPV1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9808706 | 0.91 | TRPV1 (0.74) | TRPV1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL258429 | 0.91 | TRPV1 (0.74) | TRPV1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1585740 | 0.86 | TRPV1 (0.69) | TRPV1MAPTHPGDMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0559744-A1 | COMBINATIONS OF VANILLOID COMPOUNDS AND NUCLEOSIDE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 1993-09-15 | — | — | EP | claimed |
| WO-1992009285-A1 | COMBINATIONS OF VANILLOID COMPOUNDS AND PHOSPHONATE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 1992-06-11 | — | — | WO | claimed |
| WO-1992009287-A1 | COMBINATIONS OF VANILLOID COMPOUNDS AND NUCLEOSIDE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 1992-06-11 | — | — | WO | claimed |
| US-20230137573-A1 | Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent | PROPANC PTY LTD (AU) | 2023-05-04 | — | — | US | disclosed |
| CN-107625957-B | Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen | 普罗潘克股份有限公司 | 2021-06-15 | — | — | CN | disclosed |
| US-10350239-B2 | Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent | PROPANC PTY LTD (AU) | 2019-07-16 | — | — | US | disclosed |
| EP-3095458-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND CHYMOTRYPSINOGEN | PROPANC PTY LTD (AU) | 2018-07-25 | — | — | EP | disclosed |
| US-20180064753-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT | PROPANC PTY LTD (AU) | 2018-03-08 | — | — | US | disclosed |
| US-9636359-B2 | Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent | THE UNIVERSITY OF SYDNEY (AU) | 2017-05-02 | — | — | US | disclosed |
| EP-3095458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND CHYMOTRYPSINOGEN | Propanc Pty Ltd (AU) | 2016-11-23 | — | — | EP | disclosed |
| US-20120251516-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT | PROPANC PTY Ltd. (AU) | 2012-10-04 | — | — | US | disclosed |
| EP-2490711-A1 | A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT | Propanc Pty Ltd (AU) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011047434-A1 | A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT | PROPANC PTY LTD (AU) | 2011-04-28 | — | — | WO | disclosed |
| EP-0559744-A1 | COMBINATIONS OF VANILLOID COMPOUNDS AND NUCLEOSIDE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009285-A1 | COMBINATIONS OF VANILLOID COMPOUNDS AND PHOSPHONATE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1992009287-A1 | COMBINATIONS OF VANILLOID COMPOUNDS AND NUCLEOSIDE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 1992-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064753-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT | SPINT2, PRSS1, SERPINB1 | TRPV1 505/4885MAPT 4149/4885HPGD 190/4885 |
| US-10350239-B2 | Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent | SPINT2, PRSS1, SERPINB1 | TRPV1 513/4885MAPT 4157/4885HPGD 178/4885 |
| US-20120251516-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT | SPINT2, PRSS1, SERPINB1 | TRPV1 505/4885MAPT 4149/4885HPGD 190/4885 |
| US-20230137573-A1 | Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent | SPINT2, PRSS1, SERPINB1 | TRPV1 505/4885MAPT 4149/4885HPGD 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.